140 related articles for article (PubMed ID: 10547605)
21. The endocrine glands in Pompe's disease. Report of two cases.
Hui KS; Williams JC; Borit A; Rosenberg HS
Arch Pathol Lab Med; 1985 Oct; 109(10):921-5. PubMed ID: 3899054
[TBL] [Abstract][Full Text] [Related]
22. [Severe form of juvenile type II glycogenosis in a compound-heterozygous boy (Tyr-292--> Cys/Arg-854-->Stop)].
Castro-Gago M; Eirís-Puñal J; Rodríguez-Núñez A; Pintos-Martínez E; Benlloch-Marín T; Barros-Angueira F
Rev Neurol; 1999 Jul 1-15; 29(1):46-9. PubMed ID: 10528311
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
[TBL] [Abstract][Full Text] [Related]
24. [Enzyme replacement therapy in Pompe's disease].
Merk T; Wibmer T; Schumann C; Krüger S
Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875
[TBL] [Abstract][Full Text] [Related]
25. Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse.
Fuller M; Duplock S; Turner C; Davey P; Brooks DA; Hopwood JJ; Meikle PJ
Anal Biochem; 2012 Feb; 421(2):759-63. PubMed ID: 22239964
[TBL] [Abstract][Full Text] [Related]
26. [Ichthyosiform scaling in alpha-1,4-glucosidase deficiency].
Gebhart W; Mainitz M; Jurecka W; Niebauer G; Paschke E; Stöckler S; Sluga E
Hautarzt; 1988 Apr; 39(4):228-32. PubMed ID: 3290163
[TBL] [Abstract][Full Text] [Related]
27. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Lin CY; Ho CH; Hsieh YH; Kikuchi T
Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
[TBL] [Abstract][Full Text] [Related]
28. Effects of non-contractile inclusions on mechanical performance of skeletal muscle.
Drost MR; Hesselink RP; Oomens CW; van der Vusse GJ
J Biomech; 2005 May; 38(5):1035-43. PubMed ID: 15797585
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
[TBL] [Abstract][Full Text] [Related]
30. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
31. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice.
Van der Ploeg AT; Kroos MA; Willemsen R; Brons NH; Reuser AJ
J Clin Invest; 1991 Feb; 87(2):513-8. PubMed ID: 1991835
[TBL] [Abstract][Full Text] [Related]
32. [26-year-old female patient with elevated liver enzymes].
Martin K; Schlotter B; Müller-Höcker J; Loeschke K; Pongratz D; Folwaczny C
Z Gastroenterol; 2002 Oct; 40(10):885-90. PubMed ID: 12436356
[TBL] [Abstract][Full Text] [Related]
33. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
[TBL] [Abstract][Full Text] [Related]
34. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Hagemans ML; Winkel LP; Van Doorn PA; Hop WJ; Loonen MC; Reuser AJ; Van der Ploeg AT
Brain; 2005 Mar; 128(Pt 3):671-7. PubMed ID: 15659425
[TBL] [Abstract][Full Text] [Related]
35. [Pompe's disease. Part I: pathogenesis and clinical features].
Illés Z; Trauninger A
Ideggyogy Sz; 2009 Jul; 62(7-8):231-43. PubMed ID: 19685701
[TBL] [Abstract][Full Text] [Related]
36. The pattern of involvement of adult-onset acid maltase deficiency at autopsy.
van der Walt JD; Swash M; Leake J; Cox EL
Muscle Nerve; 1987; 10(3):272-81. PubMed ID: 2951596
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
[TBL] [Abstract][Full Text] [Related]
38. [Glycogenosis type II, infantile variant. Report of a case and review of the literature].
García Mendoza JJ; Ortega Sánchez A; Acosta Valdez JL; Stanislawski Mielant EC; Navarro Muñoz C; Díaz-Devis C
Arch Inst Cardiol Mex; 1986; 56(4):323-6. PubMed ID: 2945526
[TBL] [Abstract][Full Text] [Related]
39. Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
Walvoort HC; Dormans JA; van den Ingh TS
J Inherit Metab Dis; 1985; 8(1):38-46. PubMed ID: 3921759
[TBL] [Abstract][Full Text] [Related]
40. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
Klinge L; Straub V; Neudorf U; Voit T
Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
